WASHINGTON, June 2 (UPI) — The U.S. Food and Drug Administration says it’s approved an injectable therapy for postmenopausal women with osteoporosis who are at high risk for fractures.
The FDA said the drug, Prolia, works to decrease the destruction of bone and increase bone mass and strength. An injection of Prolia is recommended once every six months.
Osteoporosis is a disease in which the bones become weak and are more likely to break. The National Institute of Arthritis and Musculoskeletal and Skin Diseases says 80 percent of the people in the United States with osteoporosis are women and one of every two women over age 50 will break a bone during their lifetime due to osteoporosis.
Prolia is manufactured by Amgen Manufacturing Ltd., a subsidiary of Amgen Inc. of Thousand Oaks, Calif.
Copyright 2010 United Press International, Inc. (UPI). Any reproduction, republication, redistribution and/or modification of any UPI content is expressly prohibited without UPI’s prior written consent.